Filgrastim and pegfilgrastim use in patients with neutropenia.
Myelosuppression, the reduction of platelets and red and white blood cells, is the most common side effect of chemotherapy. Filgrastim and pegfilgrastim are used to assist recovery in patients with low white blood cell counts. This article explores the dosing, efficacy, cost, and clinical considerations of filgrastim and pegfilgrastim in neutropenia care. Increased knowledge of the medications may contribute to positive patient outcomes. As the price of hospitalization increases, prophylactic dosing of filgrastim and pegfilgrastim becomes more cost effective. In addition, clinical outcomes are improved through a reduction in length of hospital stays and the need for IV antibiotic administration.
Quirion
Eva
E
School of Nursing, University of Maine, Orono, ME, USA. eva.quirion@umit.maine.edu
D016527:Drug Costs; D004347:Drug Interactions; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D016896:Treatment Outcome
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim